6 Reasons Investors Are Nervous About Amarin's Big Date With the FDA
Shares of America's favorite fish-oil stock, Amarin (NASDAQ: AMRN), have risen sixfold since the company released surprisingly positive results from the Reduce-It study last September. In a nutshell, the company's only product, a fish-oil capsule called Vascepa, appears to lower the risk of heart attacks for high-risk patients.
On Nov. 14, the company's proprietary formulation of fish oil will be the subject of an advisory committee meeting at the Food and Drug Administration. Here are six reasons investors are increasingly worried about the outcome of that meeting.
Image source: Getty Images.
Source Fool.com